Abstract:BACKGROUND:Traumatic brain injury (TBI) is a heterogeneous condition that can lead to critical LLLness-related corticosteroid insufficiency (CIRCI) causing a high mortality and morbidity. Glucocorticoids were widely used in the clinical management of TBI, but their benefit has been challenged in some studies and their efficacy, especially for treating CIRCI in TBI patients, remains unclear.METHODS:We conducted a meta-analysis of published data to determine if the controversy is related to clinical dosing and timing of glucocorticoids (GCs) application. We analyzed published reports in four databases (MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and CBMdisc). The published data were stratified into not only low- and high-dose GCs group but also short- and long-term GCs group to compare their effectiveness in improving TBI outcomes.RESULTS:We totally identified 16 reports. For low-dose patients, the pooled relative risks (RRs) for two clinical outcomes of death or a combination of death and severe disability were 0.95 (95% confidence interval (CI): 0.80 to 1.13) and 0.95 (95% CI: 0.83 to 1.09), respectively. The risks for infection and gastrointestinal bleeding were 0.85 (95% CI: 0.50 to 1.45) and 0.64 (95% CI: 0.15 to 2.70), respectively. For high-dose group, the pooled RR of death is 1.14 (95% CI: 1.06 to 1.21). The pooled RRs for infection and gastrointestinal bleeding for the high-dose patients were 1.04 (95% CI: 0.93 to 1.15) and 1.26 (95% CI: 0.92 to 1.75), respectively. For long-term use group, the pooled RRs for two clinical outcomes of death or a combination of death and severe disability were 0.98 (95% CI: 0.87 to 1.12) and 1.00 (95% CI: 0.90 to 1.11), respectively. The risks for infection and gastrointestinal bleeding were 0.88 (95% CI: 0.71 to 1.11) and 0.96 (95% CI: 0.35 to 2.66), respectively. For short-term use group, the pooled RR of death is 1.15 (95% CI: 1.07 to 1.23), and importantly the effects on infections were beneficial in terms of TBI patients suffering from CIRCI.CONCLUSIONS:This meta-analysis suggests an increased risk of death for TBI patients on a high dose and short term of glucocorticoids compared with those on a low dose and long term, for whom a trend towards clinical improvement is evident. In addition, stress-does of GCs further decrease the pneumonia incidence in TBI patients suffering from CIRCI. A large-scale multicenter randomized controlled trial is warranted for testing (1) the efficacy of stress-dose GCs treatment in the sub-acute phase of TBI (4-21 days after initial trauma), when CIRCI is most likely to occur; (2) the hypothesis that stress-dose GCs could boost patients' stress function and ensure survival.

The incidence of critical-illness-related-corticosteroid-insufficiency is associated with severity of traumatic brain injury in adult rats.

Stress-dose Hydrocortisone Reduces Critical Illness-Related Corticosteroid Insufficiency Associated with Severe Traumatic Brain Injury in Rats

Corticosteroid receptor rebalancing alleviates critical illness-related corticosteroid insufficiency after traumatic brain injury by promoting paraventricular nuclear cell survival via Akt/CREB/BDNF signaling

Progesterone administration modulates TLRs/NF-kappaB signaling pathway in rat brain after cortical contusion.

Effects of Glucocorticoids on Traumatic Brain Injury Related Critical Illness-Related Corticosteroid Insufficiency.

High-dose glucocorticoid aggravates TBI-associated corticosteroid insufficiency by inducing hypothalamic neuronal apoptosis

Critical Illness–related Corticosteroid Insufficiency after Multiple Traumas

Critical illness-related corticosteroid insufficiency after multiple traumas: a multicenter, prospective cohort study.

Correlation of Cell Apoptosis with Brain Edema and Elevated Intracranial Pressure in Traumatic Brain Injury.

Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats

Criteria to define mild, moderate, and severe traumatic brain injury in the mouse controlled cortical impact model

Concomitant Upregulation of Nuclear Factor-Kb Activity, Proinflammatory Cytokines and ICAM-1 in the Injured Brain after Cortical Contusion Trauma in a Rat Model.

Th1/Th2 Ratio Imbalance in The Rat Peripheral Blood Following TBI and Possible Mechanisms

Brain-protecting Effect of Β2-Adrenoceptor Antagonist in Rats with Traumatic Brain Injury

Cerebral hypoperfusion exacerbates vascular dysfunction after traumatic brain injury

Animal Models of Traumatic Brain Injury and Assessment of Injury Severity

A focal brain trauma model for rehabilitation study

Enhanced Cortical Expression of Myeloid Differentiation Primary Response Protein 88 (myd88) in Patients with Traumatic Brain Injury

Changes of CtyC and AIF in Brain and Effects of Them on Neuronal Cells in Rats after Traumatic Brain Injury

The Effects of Cathepsin B Inhibition in the Face of Diffuse Traumatic Brain Injury and Secondary Intracranial Pressure Elevation

Cranial Venous Outflow Obstruction Promotes Neuroinflammation And Edema Via ADAM17/solTNF-α/NF-κB Pathway In A Rat Subdural Hematoma Model